Medicare AdvantageCoverageMedium impact
MA08.127f, Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Aug 25, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated the medical necessity criteria for Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™). This change affects coverage requirements for these cancer immunotherapy drugs, likely impacting prior authorization or documentation requirements for oncology practices treating Medicare Advantage patients.
Action Required
By August 25, 2025: Oncology providers and billing teams must review updated medical necessity criteria for Tecentriq and Tecentriq Hybreza for Medicare Advantage patients. Update prior authorization workflows and ensure documentation meets new criteria requirements. Verify current authorization processes align with updated policy to prevent claim denials.